Search

Transforming recyclable materials into a suitable product is an important area of research nowadays. This report demonstrates that carbon material derived from waste printer cartridges can be exploited to fabricate electrochemical cells—particularly supercapacitors (SCs). SCs are electrochemical energy storage devices currently attracting much attention in the research community due to their salient features, such as cost-effectiveness, extended cycle stability, and durability. Here, we report the results of thoroughly examining the effects of acidic, basic, and neutral aqueous electrolytes on printer waste carbon electrode material in SC efficiency. In our work, the waste carbon collected from used printer cartridges shows a specific capacitance of 178.4 F/g with energy and power density of 24.77 Wh/kg and 999.68 W/kg, respectively, at 0.5 A/g current density in acidic (1 M H2SO4) electrolyte medium. Moreover, it exhibited very promising capacitance of 135.04 F/g and 87.04 F/g in basic (1 M LiOH) and neutral (1 M NaCl) electrolyte medium, respectively, at 0.8 A/g current density with considerably better cycle stability. In an acidic medium, printer waste carbon drives a DC motor for 1 min with a three-cell series arrangement. The properties of that waste carbon (extracted from the cartridges) are similar to high-rate activated carbon available commercially. [ABSTRACT FROM AUTHOR]

Highly polymorphic BCR-ABL kinase domains have been reported to harbor more than a hundred mutations, and among these, 40–60% have been identified as influencers of imatinib mesylate (IM) resistance. The emergence of IM resistance poses a significant challenge in the management of Chronic Myeloid Leukemia (CML). M351T (rs121913457), E255K (rs387906517), and Y253H (rs121913461) are of particular clinical significance due to their association with high-level imatinib resistance. This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance. During the study period from 2018 to 2022 (48 months), the blood samples from 219 Reverse transcriptase-PCR-confirmed CML patients following RNA extraction and cDNA preparation were subjected to M351T, E255K, and Y253H mutation analysis by PCR–RFLP. After agarose gel visualization, the samples were subjected to Sanger sequencing to confirm the nucleotide change at the polymorphic loci. The wild-type genotype of all three ABL1 SNPs under investigation exhibits a significant reduction in frequency among IM non-responders compared to the responder group. The CGT haplotype frequency exhibits a significant difference between IM responder (4.2%) and non-responder (11.8%) (p = 0.002 < 0.05). Further, CGC haplotype was observed solely among the imatinib non-responder patients with a frequency percentage of 3.3% (p = 0.004), whereas the said genotype was absent among the responder group. A reduced overall survival rate was observed with deviation from wild-type genotype (M351T loci (T > C) with 1.217 times, E255K (G > A) with 1.485 and Y253H (T > C) with 1.399 times increase in hazard ratio) thereby enhancing mortality risk due to disease progression. The significant increase in the frequency of M351T, E255K, and Y253H loci among the IM non-responder group indicated their probable association with the development of IM resistance among CML patients. A haplotype frequency distribution pattern analysis of ABL1 loci further identified the CGC haplotype as an independent predictor for IM resistance. As such the study highlights the importance of patient characteristics, genotype distribution, and haplotype frequency distribution in predicting the response to IM treatment and clinical outcomes of CML patients. [ABSTRACT FROM AUTHOR]